{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:49:25Z","timestamp":1791748165796,"version":"4.3.4"},"reference-count":80,"publisher":"Japan Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1507\/endocrj.ej17-0323","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T22:10:57Z","timestamp":1506723057000},"page":"1043-1053","source":"Crossref","is-referenced-by-count":78,"title":["Interaction between bone and glucose metabolism [Review]"],"prefix":"10.1507","volume":"64","author":[{"given":"Ippei","family":"Kanazawa","sequence":"first","affiliation":[{"name":"Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int<\/i> 18: 427-444.","DOI":"10.1007\/s00198-006-0253-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol<\/i> 166: 495-505.","DOI":"10.1093\/aje\/kwm106"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T (2009) Diabetic patients have an increased risk of vertebral fractures independent of bone mineral density or diabetic complications. J Bone Miner Res<\/i> 24: 702-709.","DOI":"10.1359\/jbmr.081207"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4.Saito M, Fujii K, Mori Y, Marumo K (2006) Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN\/Kob rats. Osteoporos Int<\/i>17: 1514-1523.","DOI":"10.1007\/s00198-006-0155-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kanazawa I, Tomita T, Miyazaki S, Ozawa E, Yamamoto LA, et al<\/i>. (2017) Bazedoxifene ameliorates homocysteine-induced apoptosis and accumulation of advanced glycation end products by reducing oxidative stress in MC3T3-E1 cells. Calcif Tissue Int<\/i> 100: 286-297.","DOI":"10.1007\/s00223-016-0211-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, et al<\/i>. (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell<\/i> 142: 296-308.","DOI":"10.1016\/j.cell.2010.06.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Thrailkill KM (2000) Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther<\/i> 2: 69-80.","DOI":"10.1089\/152091599316775"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kanazawa I, Yamaguchi T, Sugimoto T (2011) Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int<\/i> 22: 1191-1198.","DOI":"10.1007\/s00198-010-1310-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, et al<\/i>. (2009) Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol<\/i> 160: 265-273.","DOI":"10.1530\/EJE-08-0642"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, et al<\/i>. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell<\/i> 130: 456-469.","DOI":"10.1016\/j.cell.2007.05.047"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, et al<\/i>. (2007) Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol<\/i> 8: 51.","DOI":"10.1186\/1471-2121-8-51"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2009) Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. Am J Physiol Endocrinol Metab<\/i> 296: E139-146.","DOI":"10.1152\/ajpendo.90677.2008"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun<\/i> 375: 414-419.","DOI":"10.1016\/j.bbrc.2008.08.034"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Takeno A, Kanazawa I, Tanaka K, Notsu M, Yokomoto M, et al<\/i>. (2015) Activation of AMPK-activated protein kinase protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2. Bone<\/i> 77: 135-141.","DOI":"10.1016\/j.bone.2015.04.025"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Grandhee SK, Monnier VM (1991) Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem<\/i> 266: 11649-11653.","DOI":"10.1016\/S0021-9258(18)99006-X"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, et al<\/i>. (2009) Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab<\/i> 94: 2380-2386.","DOI":"10.1210\/jc.2008-2498"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T (2008) Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab<\/i> 93: 1013-1019.","DOI":"10.1210\/jc.2007-1270"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Farlay D, Armas LA, Gineyts E, Akhter MP, Recker RR, et al<\/i>. (2016) Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res<\/i> 31: 190-195.","DOI":"10.1002\/jbmr.2607"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hygum K, Starup-Linde J, Harslof T, Vestergaard P, Langdahl BL (2017) Mechanisms in endocrinology: Diabetes mellitus, a state of low bone turnover – a systematic review and meta-analysis. Eur J Endocrinol<\/i> 176: R137-157.","DOI":"10.1530\/EJE-16-0652"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kunutsor SK, Apekey TA, Laukkanen JA (2015) Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence. Eur J Epidemiol<\/i> 30: 599-614.","DOI":"10.1007\/s10654-015-0058-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, et al<\/i>. (2009) Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab<\/i> 94: 3031-3037.","DOI":"10.1210\/jc.2008-2187"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, et al<\/i>. (2009) Serum osteocalcin\/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int<\/i> 85: 228-234.","DOI":"10.1007\/s00223-009-9272-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone<\/i> 96: 29-37.","DOI":"10.1016\/j.bone.2016.10.007"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yamamoto M, Yamauchi M, Sugimoto T (2013) Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab<\/i> 98: 4030-4037.","DOI":"10.1210\/jc.2013-2143"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mercer N, Ahmed H, Etcheverry SB, Vasta GR, Cortizo AM (2007) Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem<\/i> 306: 87-94.","DOI":"10.1007\/s11010-007-9557-8"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T (2015) Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun<\/i> 461: 193-199.","DOI":"10.1016\/j.bbrc.2015.02.091"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, et al<\/i>. (2007) The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res<\/i> 39: 871-875.","DOI":"10.1055\/s-2007-991157"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Okazaki K, Yamaguchi T, Tanaka K, Notsu M, Ogawa N, et al<\/i>. (2012) Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int<\/i> 91: 286-296.","DOI":"10.1007\/s00223-012-9641-2"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Notsu M, Yamaguchi T, Okazaki K, Tanaka K, Ogawa N, et al<\/i>. (2014) Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β expression and secretion. Endocrinology<\/i> 155: 2402-2410.","DOI":"10.1210\/en.2013-1818"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Tanaka K, Yamaguchi T, Kaji H, Kanazawa I, Sugimoto T (2013) Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activation endoplasmic reticulum stress. Biochem Biophys Res Commun<\/i> 438: 463-467.","DOI":"10.1016\/j.bbrc.2013.07.126"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, et al<\/i>. (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med<\/i> 350: 2033-2041.","DOI":"10.1056\/NEJMoa032546"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Yang J, Hu X, Zhang Q, Cao H, Wang J, et al<\/i>. (2012) Homocysteine level and risk of fracture: A meta-analysis and systematic review. Bone<\/i> 51: 376-382.","DOI":"10.1016\/j.bone.2012.05.024"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Li J, Zhang H, Yan L, Xie M, Chen J (2014) Fracture is additionally attributed to hyperhomocysteinemia in men and premenopausal women with type 2 diabetes. J Diabetes Investig<\/i> 5: 236-241.","DOI":"10.1111\/jdi.12149"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, et al<\/i>. (2010) Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int<\/i> 21: 655-666.","DOI":"10.1007\/s00198-009-0980-4"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Takeno A, Kanazawa I, Tanaka K, Notsu M, Yokomoto-Umakoshi M, et al<\/i>. (2016) Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 and 2. Endocr J<\/i> 63: 389-395.","DOI":"10.1507\/endocrj.EJ15-0480"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Verhaeghe J, Suiker AM, Visser WJ, Van Herck E, Van Bree R, et al<\/i>. (1992) The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. J Endocrinol<\/i> 134: 485-492.","DOI":"10.1677\/joe.0.1340485"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Janghorbani M, Feskanich D, Willett WC, Hu F (2006) Prospective study of diabetes and risk of hip fracture: the Nurses’ Health Study. Diabetes Care<\/i> 29: 1573-1578.","DOI":"10.2337\/dc06-0440"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG (2000) Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest<\/i> 23: 295-303.","DOI":"10.1007\/BF03343726"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Pun KK, Lau P, Ho PW (1989) The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res<\/i> 4: 853-862.","DOI":"10.1002\/jbmr.5650040610"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kream BE, Smith MD, Canalis E, Raisz LG (1985) Characterization of the effect of insulin on collagen synthesis in fetal rat bone. Endocrinology<\/i> 116: 296-302.","DOI":"10.1210\/endo-116-1-296"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Fulzele K, Riddle RC, Digirolamo DJ, Cao X, Wan C, et al<\/i>. (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell<\/i> 142: 309-319.","DOI":"10.1016\/j.cell.2010.06.002"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, et al<\/i>. (2002) Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals and essential role of IGF signaling in bone matrix mineralization. J Biol Chem<\/i> 277: 44005-44012.","DOI":"10.1074\/jbc.M208265200"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, et al<\/i>. (2002) Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest<\/i> 110: 771-781.","DOI":"10.1172\/JCI0215463"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Terada M, Inaba M, Yano Y, Hasuma Y, Nishizawa Y, et al<\/i>. (1998) Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone<\/i> 22: 17-23.","DOI":"10.1016\/S8756-3282(97)00220-2"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. McCarthy AD, Etcheverry SB, Cortizo AM (2001) Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol<\/i> 38: 113-122.","DOI":"10.1007\/s005920170007"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, et al<\/i>. (2007) Serum insulin-like growth factor-I is associated with the presence of vertebral fractures in postmonopausal women with type 2 diabetes mellitus. Osteoporos Int<\/i> 18: 1675-1681.","DOI":"10.1007\/s00198-007-0430-0"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, et al<\/i>. (2005) Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res<\/i> 309: 99-109.","DOI":"10.1016\/j.yexcr.2005.05.021"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, et al<\/i>. (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res<\/i> 21: 1648-1656.","DOI":"10.1359\/jbmr.060707"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD (2007) Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab<\/i> 92: 1517-1523.","DOI":"10.1210\/jc.2006-2097"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Johansson H, Oden A, Karlsson MK, McCloskey E, Kanis JA, et al<\/i>. (2014) Waning predictive value of serum adiponectin for fracture risk in elderly men: MrOS Sweden. Osteoporos Int<\/i> 25: 1831-1836.","DOI":"10.1007\/s00198-014-2654-0"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Desbois C, Hogue DA, Karsenty G (1994) The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. J Biol Chem<\/i> 269: 1183-1190.","DOI":"10.1016\/S0021-9258(17)42240-X"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, et al<\/i>. (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res<\/i> 24: 785-791.","DOI":"10.1359\/jbmr.081234"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Fernandez-Real JM, Izquierdo M, Ortega F, Gorostiaga E, Gomez-Ambrosi J, et al<\/i>. (2009) The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab<\/i> 94: 237-245.","DOI":"10.1210\/jc.2008-0270"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Pitass AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B (2009) Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab<\/i> 94: 827-832.","DOI":"10.1210\/jc.2008-1422"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, et al<\/i>. (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab<\/i> 94: 45-49.","DOI":"10.1210\/jc.2008-1455"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, et al<\/i>. (2011) Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone<\/i> 48: 720-725.","DOI":"10.1016\/j.bone.2010.12.020"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Kanazawa I, Yamaguchi T, Sugimoto T (2011) Relationship between bone biochemical markers versus glucose\/lipid metabolism and atherosclerosis; a longitudinal study in type 2 diabetes mellitus. Diabetes Res Clin Pract<\/i> 92: 393-399.","DOI":"10.1016\/j.diabres.2011.03.015"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, et al<\/i>. (2011) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int<\/i> 22: 187-194.","DOI":"10.1007\/s00198-010-1184-7"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Hwang YC, Jeong IK, Ahn KJ, Chung HY (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β-cell function in middle-aged male subjects. Diabetes Metab Res Rev<\/i> 25: 768-772.","DOI":"10.1002\/dmrr.1045"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Iki M, Tamaki J, Fujita Y, Kouda K, Yura A, et al<\/i>. (2012) Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int<\/i> 23: 761-770.","DOI":"10.1007\/s00198-011-1600-7"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab<\/i> 1: 15-25.","DOI":"10.1016\/j.cmet.2004.12.003"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Ruderman NB, Carling D, Prentki M, Cacicedo JM (2013) AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest<\/i> 123: 2764-2772.","DOI":"10.1172\/JCI67227"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Motoshima H, Goldstein BJ, Igata M, Araki E (2006) AMPK and cell proliferation- AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol<\/i> 574: 63-71.","DOI":"10.1113\/jphysiol.2006.108324"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Salminen A, Hyttinen JM, Kaarniranta K (2011) AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on health span and lifespan. J Mol Med<\/i> (Berl) 89: 667-676.","DOI":"10.1007\/s00109-011-0748-0"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Quinn JM, Tam S, Sims NA, Saleh H, McGregor NE, et al<\/i>. (2010) Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J<\/i> 24: 275-285.","DOI":"10.1096\/fj.09-137158"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, et al<\/i>. (2010) AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone<\/i> 47: 309-319.","DOI":"10.1016\/j.bone.2010.04.596"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Jeyabalan J, Shah M, Viollet B, Chenu C (2012) AMP-activated protein kinase pathway and bone metabolism. J Endocrinol<\/i> 212: 277-290.","DOI":"10.1530\/JOE-11-0306"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, et al<\/i>. (2010) AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone<\/i> 47: 309-319.","DOI":"10.1016\/j.bone.2010.04.596"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Jang WG, Kim EJ, Lee KN, Son HJ, Koh JT (2011) AMP-activated protein kinase (AMPK) positively regulates osteoblast differentiation via induction of Dlx5-dependent Runx2 expression in MC3T3E1 cells. Biochem Biophys Res Commun<\/i> 404: 1004-1009.","DOI":"10.1016\/j.bbrc.2010.12.099"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Lee YS, Kim YS, Lee SY, Kim GH, Kim BJ, et al<\/i>. (2010) AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone<\/i> 47: 926-937.","DOI":"10.1016\/j.bone.2010.08.001"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Kang H, Viollet B, Wu D (2013) Genetic deletion of catalytic subunits of AMP-activated protein kinase increases osteoclasts and reduces bone mass in young adult mice. J Biol Chem<\/i> 288: 12187-12196.","DOI":"10.1074\/jbc.M112.430389"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, et al<\/i>. (2011) Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 112: 2902-2909.","DOI":"10.1002\/jcb.23206"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Yokomoto-Umakoshi M, Kanazawa I, Takeno A, Tanaka K, Notsu M, et al<\/i>. (2016) Activation of AMP-activated protein kinase decreases receptor activator of NF-κB ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells. Biochem Biophys Res Commun<\/i> 469: 791-796.","DOI":"10.1016\/j.bbrc.2015.12.072"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Jeyabalan J, Shah M, Viollet B, Roux JP, Chavassieux P, et al<\/i>. (2012) Mice lacking AMP-activated protein kinase α1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment. J Endocrinol<\/i> 214: 349-358.","DOI":"10.1530\/JOE-12-0184"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Tulipano G, Faggi L, Sibilia V, Giustina A (2012) Points of integration between the intracellular energy sensor AMP-activated protein kinase (AMPK) activity and the somatotroph axis function. Endocrine<\/i> 42: 292-298.","DOI":"10.1007\/s12020-012-9732-x"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Xi G, Rosen CJ, Clemmons DR (2016) IGF-I and IGFBP-2 stimulate AMPK activation and autophagy, which are required for osteoblast differentiation. Endocrinology<\/i> 157: 268-281.","DOI":"10.1210\/en.2015-1690"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Li Y, Li K (2014) Osteocalcin induced growth hormone\/insulin-like growth factor-1 system by promoting testosterone synthesis in male mice. Horm Metab Res<\/i> 46: 768-773.","DOI":"10.1055\/s-0034-1371869"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G (2012) Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone<\/i> 50: 568-575.","DOI":"10.1016\/j.bone.2011.04.017"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia<\/i> 48: 1292-1299.","DOI":"10.1007\/s00125-005-1786-3"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Melton LJ 3rd, Leibson CL, Achenbach SJ, Themeau TM, Khosla S (2008) Fracture risk in type 2 diabetes: Update of a population-based study. J Bone Miner Res<\/i> 23: 1334-1342.","DOI":"10.1359\/jbmr.080323"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/11\/64_EJ17-0323\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T19:54:14Z","timestamp":1659556454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/11\/64_EJ17-0323\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej17-0323","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}